NEW YORK, November 4 (newratings.com) – The US Food & Drug Administration (FDA) has asked VaxGen Inc ( VXGN.NAS ) to postpone the advanced testing of its anthrax vaccine owing to fears that the drug may not be stable enough to pass the trials. VaxGen’s share price fell by 56% to $1.77 on Friday.